, Directive 2001/83/CE du Parlement européen et du Conseil du 6 novemvre 2001 instituant un code communautaire relatif aux médicaments à usage humain. JO L 311 du 28 novembre, p.67, 2001.

, établissant des procédures communautaires pour l'autorisation et la surveillance des médicaments à usage humain et à usage vétérinaire et instituant une agence européenne pour l'évaluation des médicaments, 1993.

C. Ema, Guideline on similar biological medicinal products, vol.23

, mars 2004 modifiant la directive 2001/83/CE instituant un code communautaire relatif aux médicaments à usage humain. JO L 136 du 30 avril, 2004.

A. Marchand, Opothérapie : émergence et développement d'une technique thérapeutique (France, 1889-1940)

F. Paris, Ecole doctorale Abbé Grégoire, 2014.

H. Bazin, Histoire des vaccinations, John Libbey Eurotext, vol.474, 2008.

. Médicament, ADSP, vol.23, issue.27, p.24, 1999.

, Fédération Française des diabétiques. Les 90 ans de la découverte de l'insuline

. Pfizer, Les biosimilaires en 10 questions

D. Sur,

L. Pen and C. , Les biosimilaires en 15 questions, p.23, 2014.

D. Sur,

A. L. Berthier, . La, and . Le-biosimilaire-omnitrope®-de-sandoz, , 2006.

G. Walsh, Biopharmaceutical benchmarks, Nat Biotechnol, vol.36, issue.12, pp.1136-1145, 2018.

. Oms, A. Le-système, and . Intérêt-en-pharmacovigilance,

D. Sur,

, ANSM. Les médicaments biosimilaires

D. Sur,

. Ema, Public statement lusduna withdrawal marketing authorisation european union, 2018.

D. Sur,

P. Paubel, Actualités sur les biosimilaires, vol.12

D. Piedade, Biosimilar medicines: a cost-effective move towards patient access, 2018.

D. Sur,

. Ansm, Etat des lieux sur les médicaments biosimilaires

. Ansm, Médicaments biosimilaires -Point d'information

D. Sur,

. Roche, L'essentiel sur les anticorps thérapeutiques, 2015.

D. Sur,

C. E. Ema, Les médicaments biosimilaires dans l'UE Guide d'information destiné aux professionnels de la santé, p.24, 2017.

A. Abraham, De la structure primaire à la structure quaternaire

. Researchgate,

C. Housset, A. Raisonnier, and . Biologie-moléculaire, , 2009.

D. Sur,

M. Sève, Les protéines recombinantes, 2015.

M. Sève, Les modifications post-traductionnelles. Grenoble, 2011.

R. A. Mckinnon, M. Cook, W. Liauw, M. Marabani, I. C. Marschner et al., Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review, BioDrugs. févr, vol.32, issue.1, pp.27-52, 2018.

. Ars-santé, « Les médicaments biosimilaires ? ? à vos marques, prêts, prescrivez !

, Janvier, vol.22, p.742, 2018.

P. M. Sève, Les protéines recombinantes : historiques, perspectives, contrôle et réglementation. Grenoble, 2014.

E. Levacher, B. Gatefin, and J. Grugier, Culture cellulaire : Trois étapes clés pour produire des protéines thérapeutiques. 1 avr, 2011.

D. Sur,

E. Ich, Topic Q 6 B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products, vol.17, 1999.

J. F. Lee, J. B. Litten, and G. Grampp, Comparability and biosimilarity: considerations for the healthcare provider, Curr Med Res Opin, vol.28, issue.6, pp.1053-1061, 2012.

J. Abraham, International Conference On Harmonisation Of Technical Requirements For Registration Of Pharmaceuticals For Human Use. In: Brouder A, Tietje C, éditeurs. Handbook of Transnational Economic Governance Regimes, pp.1041-54, 2009.

C. Ema, Guideline on comparability of biotechnology-derived medicinal products after a change in the manufacturing process, 2017.

D. Sur,

J. Prugnaud, Similarité des médicaments issus des biotechnologies : cadre réglementaire et spécificité, Ann Pharm Fr. août, vol.66, issue.4, pp.206-217, 2008.

P. Galais, Marketing Authorization of the Biosimilars, 2017.

F. B. Vincent, E. F. Morand, K. Murphy, F. Mackay, X. Mariette et al., Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective, Ann Rheum Dis. févr, vol.72, issue.2, pp.165-78, 2013.

M. Biggioggero, M. Danova, U. Genovese, F. Locatelli, P. L. Meroni et al., The challenging definition of naïve patient for biological drug use, Autoimmun Rev. juin, vol.14, issue.6, pp.543-549, 2015.

A. V. Klein, J. Wang, B. G. Feagan, and M. Omoto, Biosimilars: State of Clinical and Regulatory Science, J Pharm Pharm Sci. 12 sept, vol.20, issue.1, p.332, 2017.

M. C. Béné, C. André, Y. Lebranchu, A. Chevailler, C. Hoarau et al., Europe : les brevets contre l'accès aux médicaments, Prescrire. Mai, vol.29, issue.307, p.375, 2009.

. Omc, Les brevets pharmaceutiques et l'Accord sur les ADPIC

D. Sur,

L. Le,

. European-patent-office and . Faq--japon,

D. Sur,

J. D. Schakowsky and . R. Text--h, 6577 -115th Congress, PRICED Act, 2017.

, USC 262: Regulation of biological products

D. Sur,

E. Biosimilar, Medicinal Products Working Party, 2018.

D. Sur, Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, MHLW. Guideline for the Quality, Safety, and Efficacy Assurance of Follow-on Biologics, 2009.

G. Online, Biosimilars approved in Japan, 2018.

D. Sur,

T. Arato, Japanese regulation of biosimilar products: past experience and current challenges: Japanese regulation of biosimilar products, Br J Clin Pharmacol. juill, vol.82, issue.1, pp.30-40, 2016.

V. Bhatt, Current Market and Regulatory Landscape of Biosimilars, Am J Manag Care, vol.24, issue.21, pp.451-456, 2018.

A. Sarpatwari, R. Barenie, G. Curfman, J. J. Darrow, and A. S. Kesselheim, The US Biosimilar Market: Stunted Growth and Possible Reforms, Clin Pharmacol Ther. janv, vol.105, issue.1, pp.92-100, 2019.

. Ce, Ce qu'il faut savoir sur les médicaments biosimilaires, 2013.

R. Garcia and D. V. Araujo, The Regulation of Biosimilars in Latin America, Curr Rheumatol Rep, vol.18, issue.3, 2016.

, Evaluate Pharma. World Preview, 2018.

D. Sur,

K. Jhamb, Biosimilars: Global Markets. BCC Research, 2018.

D. Sur,

, Embracing the Patent Cliff, Evaluate Pharma. World Preview, 2012.

D. Sur,

E. Moorkens, N. Meuwissen, I. Huys, P. Declerck, A. G. Vulto et al., The Market of Biopharmaceutical Medicines: A Snapshot of a Diverse Industrial Landscape. Front Pharmacol, vol.8, 2017.

B. Calo-fernández, J. Martínez-hurtado, and . Biosimilars, Company Strategies to Capture Value from the Biologics Market, Pharmaceuticals. 12 déc, vol.5, issue.12, pp.1393-408, 2012.

G. Online, Biosimilars approved in Europe, 2018.

S. Nhs-scotland, Biosimilar medicines, Mai, 2015.

G. Online, Automatic pharmacist substitution of biosimilars in Germany, 2019.

H. Larkin, J. Macdonald, and R. Lumsden, Pharmacy-mediated substitution of biosimilars -a global survey benchmarking country substitution policies, GaBI Journal, vol.6, issue.4, pp.157-64, 2017.

, Memo Positioning statements on Physician-led switching for biosimilar medicines, 2019.

J. Franklin, Biosimilar and Interchangeable Products: The U.S. FDA Perspective, p.21

. Fda,

, The PHS Act. Sect, vol.351, issue.i

, The PHS Act. Sect, vol.351, issue.4

, Biosimilar medicines Information for pharmacists, Mai 2019

D. Sur,

A. Government, Who chooses whether the biosimilar medicine or the reference biological medicine is used?, 2019.

S. C. Singh and K. M. Bagnato, The Economic Implications of Biosimilars, vol.21, p.10, 2015.

, IMS Institute for Healthcare Informatics. Delivering on the Potential of Biosimilar Mediciness : the Role of Functioning Competitive Markets, 2016.

D. Sur,

, Direction des Affaires Economiques du LEEM. Bilan économique 2018 des Entreprises du médicament

D. Sur, IQVIA. The impact of biosimilar competition in Europe, vol.40, 2018.

. Quintilesims, The impact of biosimilar competition in Europe, vol.33, 2017.

A. Inotai, C. Prins, M. Csanádi, D. Vitezic, C. Codreanu et al., Is there a reason for concern or is it just hype? -A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars, Expert Opin Biol Ther. 3 août, vol.17, issue.8, pp.915-941, 2017.

V. Razanskaite, M. Bettey, L. Downey, J. Wright, J. Callaghan et al., Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme, J Crohns Colitis, vol.7, 2017.

D. Girault, J. Trouvin, C. Blachier-poisson, F. Gary, D. Laloye et al., Biosimilaires : de la technique au médicoéconomique, Therapies. janv, vol.70, issue.1, pp.37-46, 2015.

C. Ducret, Le premier médicament au monde face au défi de la concurrence

L. Echos, , 2018.

M. Khraishi, D. Stead, M. Lukas, F. Scotte, and H. Schmid, Biosimilars: A Multidisciplinary Perspective, Clin Ther. mai, vol.38, issue.5, pp.1238-1287, 2016.

J. Daems, Remboursabilité des spécialités biosimilaires et Convention sur "la relance des médicaments biosimilaires en Belgique

. Bruxelles and . Février, , 2018.

D. Sur, Accord national médico-mutualiste, 2018.

. Bruxelles and . Décembre, , 2017.

D. Sur,

, INAMI. Médicaments biosimilaires : un incitant pour la prescription de médicaments biosimilaires en-dehors de l'hôpital, Février, p.82, 2019.

D. Sur,

J. Mestre-ferrandiz, A. Towse, and M. Berdud, Biosimilars: How Can Payers Get Long-Term Savings?, PharmacoEconomics. juin, vol.34, issue.6, pp.609-625, 2016.

E. Moorkens, A. G. Vulto, I. Huys, P. Dylst, B. Godman et al., Policies for biosimilar uptake in Europe: An overview, PLoS ONE. Décembre, vol.12, issue.12, p.190147, 2017.

. Gfk, Factors Supporting a Sustainable European Biosimilar Medicines Market

, Septembre, 2014.

S. R. Mehr and R. A. Brook, Factors influencing the economics of biosimilars in the US, J Med Econ. 2 déc, vol.20, issue.12, pp.1268-71, 2017.

R. Moots, V. Azevedo, J. L. Coindreau, T. Dörner, E. Mahgoub et al., Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician, Curr Rheumatol Rep, vol.19, issue.6, 2017.

. Ema, Guideline on good pharmacovigilance practices (GVP) Product-or Population-Specific Considerations II: Biological medicinal products, 2016.

. Fda, Guidance for Industry Immunogenicity Assessment for Therapeutic Protein Products, 2014.

P. Rocco, S. Selletti, and P. Minghetti, Biosimilar switching and related medical liability, J Forensic Leg Med. avr, vol.55, pp.93-97, 2018.

S. H. King, Protecting Access to Care Act of, 1215.

Á. Milassin, A. Fábián, and T. Molnár, Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective, Ther Adv Gastroenterol, vol.12, p.175628481984274, 2019.

K. K. Jørgensen, I. C. Olsen, G. L. Goll, M. Lorentzen, N. Bolstad et al., Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. The Lancet, vol.389, pp.2304-2320, 2017.

. Fda, Considerations in Demonstrating Interchangeability With a Reference Product Guidance for Industry

E. Pharmacovigilance,

. Ansm, Médicaments faisant l'objet d'un plan de gestion des risques (PGR)

D. Sur,

S. Francescon, G. Fornasier, and P. Baldo, EU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodies, Int J Clin Pharm. Août, vol.40, issue.4, pp.778-82, 2018.

. Ema, Post-authorisation safety studies (PASS)

D. Sur,

P. Wiland, B. Batko, M. Brzosko, E. J. Kucharz, W. Samborski et al., Biosimilar switching -current state of knowledge, Reumatologia/Rheumatology, vol.56, issue.4, pp.234-276, 2018.

. Portela-m-da-cc, C. Sinogas, A. De-almeida, F. Baptista-leite, R. Castro-caldas et al., Biologicals and biosimilars: safety issues in Europe, Expert Opin Biol Ther. 3 juillet, vol.17, issue.7, pp.871-878, 2017.

N. S. Vermeer, S. Straus, A. K. Mantel-teeuwisse, F. Domergue, T. Egberts et al., Traceability of Biopharmaceuticals in Spontaneous Reporting Systems: A Cross-Sectional Study in the FDA Adverse Event Reporting System (FAERS) and EudraVigilance Databases, Drug Saf. Août, vol.36, issue.8, pp.617-642, 2013.

, Qu'est-ce que le Dossier Pharmaceutique ?, 2019.

G. Online, WHO says more communication and education needed to increase access to biosimilars, Mai 2019

E. Leonard, M. Wascovich, S. Oskouei, P. Gurz, and D. Carpenter, Factors Affecting Health Care Provider Knowledge and Acceptance of Biosimilar Medicines: A Systematic Review, J Manag Care Spec Pharm. janv, vol.25, issue.1, pp.102-114, 2019.

H. Kellner, E. Domènech, P. L. Lakatos, J. Marsal, C. Agboton et al., AB0314 Awareness and Acceptance of Biosimilars by Rheumatologists in Eleven Eu Countries, Ann Rheum Dis. juin, vol.75, issue.2, pp.1008-1009, 2016.

M. Beck, B. Michel, M. Rybarczykvigouret, D. Levêque, and C. Sordet, Rheumatologists' Perceptions of Biosimilar Medicines Prescription: Findings from a French Web-Based Survey, On behalf of the CRI (Club "Rhumatismes et Inflammations"), vol.30, pp.585-92, 2016.

S. R. Chapman, R. W. Fitzpatrick, and M. I. Aladul, Knowledge, attitude and practice of healthcare professionals towards infliximab and insulin glargine biosimilars: result of a UK web-based survey, BMJ Open. juin, vol.7, issue.6, p.16730, 2017.

S. Danese, G. Fiorino, and P. Michetti, Changes in Biosimilar Knowledge among European Crohn's Colitis Organization [ECCO] Members: An Updated Survey, J Crohns Colitis, vol.10, issue.11, pp.1362-1367, 2016.

J. O'callaghan, M. Bermingham, M. Leonard, F. Hallinan, J. M. Morris et al., Assessing awareness and attitudes of healthcare professionals on the use of biosimilar medicines: A survey of physicians and pharmacists in Ireland, Regul Toxicol Pharmacol. août, vol.88, pp.252-61, 2017.

. Esno and . Switch, Management between similar biological medicines, 2018.

M. F. Rezk and B. Pieper, Treatment Outcomes with Biosimilars: Be Aware of the Nocebo Effect, Rheumatol Ther. déc, vol.4, issue.2, pp.209-227, 2017.

. Ce, Que dois-je savoir sur les médicaments biosimilaires -Information pour les patients, 2016.

. Ema, Improving understanding of biosimilars in the EU, 2018.

. Fda and . Biosimilars, , 2018.

. Fda and . Biosimilars, ACTION PLAN: Balancing Innovation and Competition, Juillet, 2018.

, Een praktische handleiding voor succesvolle implementatie van biosimilars in de medisch specialistische zorg, 2017.

. Sandoz, . Les, and . Sandoz, , 2017.

D. Sur,

. Sandoz, En savoir plus sur les biosimilaires, 2017.